![Claes Lindblad](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Claes Lindblad
Direttore Finanziario/CFO presso
MODUS THERAPEUTICS HOLDING AB
Profilo
Claes Lindblad is currently Chief Financial Officer & Head-Investor Relations at Modus Therapeutics Holding AB since 2021.
Formerly, Mr. Lindblad was Manager-National Sales at Nycomed AB from 2009 to 2012, Country Manager at ConvaTec (Sweden) AB from 2012 to 2016, and Chief Financial Officer & Secretary at OssDsign AB from 2016 to 2020.
Education includes a graduate degree from Karlstad University and an MBA from Edinburgh Business School.
Posizioni attive di Claes Lindblad
| Società | Posizione | Inizio |
|---|---|---|
| MODUS THERAPEUTICS HOLDING AB | Direttore Finanziario/CFO | 15/03/2021 |
Precedenti posizioni note di Claes Lindblad
| Società | Posizione | Fine |
|---|---|---|
| OSSDSIGN AB | Direttore Finanziario/CFO | 01/01/2020 |
ConvaTec (Sweden) AB | Direttore/Membro del Consiglio | 01/03/2016 |
Nycomed AB
 Nycomed AB Pharmaceuticals: MajorHealth Technology Provides medicines and products for hospitals, specialists and general practitioners | Vendite & Marketing | 01/07/2012 |
Formazione di Claes Lindblad
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
4
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Karlstad University
 Karlstad University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nycomed AB
Nycomed AB Pharmaceuticals: MajorHealth Technology Provides medicines and products for hospitals, specialists and general practitioners | Health Technology |
ConvaTec (Sweden) AB | |
OssDsign AB
 OssDsign AB Medical SpecialtiesHealth Technology Designs, manufactures and markets implants for healing and treatment of bone defects | Health Technology |
Modus Therapeutics Holding AB
 Modus Therapeutics Holding AB BiotechnologyHealth Technology Develops sevuparin to treat people suffering from sickle cell disease | Health Technology |
Edinburgh Business School
 Edinburgh Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
